A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
BerGenBio ASA
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Fore Biotherapeutics
Celgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)